LGVN Profile
Longeveron Inc. is a clinical-stage biotechnology firm focused on advancing cellular therapies aimed at addressing aging-related and life-threatening conditions. The company is pioneering the development of innovative treatments utilizing its lead investigational product, LOMECEL-B. This product is a cell-based therapy derived from culture-expanded medicinal signaling cells obtained from the bone marrow of young, healthy adult donors. LOMECEL-B is designed to harness the regenerative properties of these cells to potentially improve health outcomes in a range of severe medical conditions.
Longeveron is actively engaged in conducting Phase 1 and Phase 2 clinical trials to evaluate the efficacy and safety of LOMECEL-B across various indications. These include aging frailty, Alzheimer’s disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company’s research aims to address critical gaps in treatment options for these challenging conditions by leveraging its proprietary cell therapy technology to potentially restore or enhance physiological function.
The company’s research efforts are underscored by its commitment to developing therapies that could transform the management of complex medical conditions associated with aging and other severe health issues. Longeveron’s clinical trials are designed to assess not only the therapeutic benefits of LOMECEL-B but also its safety profile, paving the way for future advancements in regenerative medicine.
Founded in 2014, Longeveron is headquartered in Miami, Florida. The company continues to advance its clinical programs and expand its research capabilities with the goal of delivering breakthrough treatments that could significantly impact the quality of life for patients with aging-related and critical health conditions.
|
